Valuation: VolitionRx Limited

Market Cap 5.98M 5.2M 4.84M 4.44M 8.39M 571M 8.52M 57.05M 22.39M 284M 22.47M 21.97M 953M P/E 2026 *
-0.32x
P/E 2027 * -0.52x
Enterprise Value 5.98M 5.2M 4.84M 4.44M 8.39M 571M 8.52M 57.05M 22.39M 284M 22.47M 21.97M 953M EV / Sales 2026 *
2.41x
EV / Sales 2027 * 1.04x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-10.20%
1 week-28.19%
1 month-46.81%
3 months-72.59%
6 months-87.40%
Current year-85.95%
1 week 0.69
Extreme 0.6901
1.01
1 month 0.69
Extreme 0.6901
1.53
Current year 0.69
Extreme 0.6901
7.73
1 year 0.69
Extreme 0.6901
15.1
3 years 0.69
Extreme 0.6901
27.6
5 years 0.69
Extreme 0.6901
82.8
10 years 0.69
Extreme 0.6901
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
17/3/26 Tax

Company Secretary

3,948 0.0029%
17/3/26 Tax

Chief Technology Officer

5,310 0.0039%
1/3/26
Concord International, Inc.
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-10.20%-28.19%-94.40%-97.32% 5.98M
-22.52%-18.18%+97.02%+68.74% 3.69B
-6.66%+1.35%+120.41%+167.42% 3.59B
-13.22%-18.44%+58.37%-43.94% 1.82B
+3.44%+4.55%-28.26%-36.48% 2.17B
+14.72%+17.69%+255.80%+300.64% 2.26B
-2.67%-2.81%+180.77%-41.91% 969M
+6.96%-1.82%-9.43%+15.45% 853M
+1.29%+6.41%-37.76%-14.48% 511M
+7.90%-3.22%-2.47% - 449M
Average -2.10%-5.39%+54.01%+35.35% 1.63B
Weighted average by Cap. -5.07%-3.69%+95.56%+84.43%

Financials

2026 *2027 *
Net sales 2.48M 2.15M 2M 1.84M 3.48M 237M 3.53M 23.63M 9.27M 118M 9.31M 9.1M 395M 5.73M 4.98M 4.64M 4.26M 8.04M 547M 8.17M 54.68M 21.46M 272M 21.53M 21.06M 914M
Net income -22.2M -19.3M -17.97M -16.49M -31.15M -2.12B -31.63M -212M -83.11M -1.06B -83.39M -81.55M -3.54B -19.62M -17.05M -15.87M -14.57M -27.52M -1.87B -27.95M -187M -73.44M -932M -73.68M -72.06M -3.13B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
31/07/26 USD 0.7181 -10.20% 252,637
30/07/26 USD 0.7997 +3.51% 1,006,754
29/07/26 USD 0.7726 -9.24% 249,672
28/07/26 USD 0.8513 -3.26% 397,739
27/07/26 USD 0.8800 -12.00% 232,278
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.7181USD
Average target price
16.97USD
Spread / Average Target
+2,262.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock